VSTM
Verastem, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.20
+2.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 87.5M | 30.9M | 10.0M | — | 2.6M |
| Cost of Revenue | 11.7M | 5.3M | — | — | — |
| Gross Profit | 75.9M | 25.6M | 10.0M | — | 2.6M |
| Operating Expenses | |||||
| R&D Expense | 140.2M | 114.6M | 81.3M | 61.4M | 50.6M |
| SG&A Expense | 95.2M | 81.1M | 43.6M | 30.7M | 25.0M |
| General & Admin Expense | 27.4M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 290.0K | — | — | — | — |
| Total Operating Expenses | 235.7M | 195.7M | 125.0M | 92.1M | 75.5M |
| Cost and Expenses | 247.3M | 201.0M | 125.0M | 92.1M | 75.5M |
| Operating Income (EBIT) | (159.8M) | (170.1M) | (115.0M) | (92.1M) | (72.9M) |
| Non-Operating | |||||
| Interest Income | 4.7M | 4.1M | 4.1M | 6.2M | 1.2M |
| Interest Expense | 1.5M | 1.1M | 4.6M | 4.1M | 2.1M |
| Net Interest Income | 3.2M | 2.9M | (413.0K) | 2.1M | (922.0K) |
| Other Non-Op Income/Expense | (42.1M) | (39.3M) | (15.5M) | 4.7M | (875.0K) |
| Non-Operating Income (excl Interest) | 40.9M | 38.2M | 10.9M | (8.9M) | (1.3M) |
| EBT (Pre-Tax Income) | (201.9M) | (209.5M) | (130.5M) | (87.4M) | (73.8M) |
| Income Tax Expense | 816.0K | — | 185.0K | — | — |
| Bottom Line | |||||
| Net Income | (202.7M) | (209.5M) | (130.6M) | (87.4M) | (73.8M) |
| Earnings from Cont. Ops | (202.7M) | (209.5M) | (130.6M) | (87.4M) | (73.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (202.7M) | (209.5M) | (130.6M) | (87.4M) | (73.8M) |
| Per Share | |||||
| Basic EPS | ($2.46) | ($3.02) | ($3.66) | ($3.96) | ($4.57) |
| Diluted EPS | ($2.46) | ($3.02) | ($3.66) | ($3.96) | ($4.57) |
| Revenue Per Share | $0.87 | $0.45 | $0.28 | $0.00 | $0.16 |
| Shares | |||||
| Basic Shares Outstanding | 100.1M | 69.3M | 35.7M | 22.1M | 16.1M |
| Diluted Shares Outstanding | 100.1M | 69.3M | 35.7M | 22.1M | 16.1M |
| Profitability Metrics | |||||
| EBITDA | (199.6M) | (207.6M) | (125.9M) | (83.2M) | (71.6M) |
| D&A | 1.1M | 728.0K | 26.0K | 62.0K | 118.0K |
| EBIT | (200.7M) | (208.3M) | (125.9M) | (83.2M) | (71.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026